Please wait while we load the requested 8-K report or click the link below:
https://last10k.com/sec-filings/report/1527728/000173112218000007/e1025_form8k.htm
March 2018
February 2018
January 2018
January 2018
November 2017
October 2017
Please wait while we load the requested 8-K report or click the link below:
https://last10k.com/sec-filings/report/1527728/000173112218000007/e1025_form8k.htm
Compare this 8-K Corporate News to its predecessor by reading our highlights to see what text and tables were removed , added and changed by Dandrit Biotech Usa, Inc..
Dandrit Biotech Usa, Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2018 10-K Annual Report includes:
Material Contracts, Statements, Certifications & more
Dandrit Biotech Usa, Inc. provided additional information to their SEC Filing as exhibits
Ticker: DDRTEvents:
CIK: 1527728
Form Type: 8-K Corporate News
Accession Number: 0001731122-18-000007
Submitted to the SEC: Tue Mar 06 2018 5:27:57 PM EST
Accepted by the SEC: Tue Mar 06 2018
Period: Wednesday, February 28, 2018
Industry: Pharmaceutical Preparations